Novavax participated in Oxford University Com-COV3 booster trial of COVID-19 vaccines in adolescents aged 12 through 15
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
-
-
Computer model predicted dominant SARS-CoV-2 variants
On May 24, 2022, scientists at the Broad Institute of MIT and Harvard and the University of Massachusetts…
-
Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…
-
NIH announced antiviral drug development awards
On May 18, 2022, the U.S. National Institutes of Health announced it had awarded approximately $577 million to…
-
Depression, loneliness associated with increased hospitalization risk after COVID-19
On May 19, 2022, the U.S. National Institutes of Health (NIH) announced that people who reported in a…
-
WHO validated 11th vaccine for COVID-19
On May 19, 2022, World Health Organization (WHO) issued an emergency use listing (EUL) for CONVIDECIA, a vaccine…
-
Labcorp received EUA for first non-prescription at-home collection kit for combined COVID-19, Flu and RSV detection
On May 18, 2022, LabCorp announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and…
-
InteliSwab COVID-19 rapid test validated to detect Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants
On May 17, 2022, OraSure Technologies announced that its InteliSwab COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1,…
-
Pfizer and BioNTech granted U.S. EUA for booster dose of COVID-19 vaccine in children 5 through 11 years of age
On May 17, 2022, Pfizer and BioNTech announced the U.S. Food and Drug Administration expanded emergency use authorization…
-
TGen worked with Arizona zoos and state and federal wildlife agencies to test wild animals for SARS-CoV-2
On May 16, 2022, working with state and federal wildlife agencies and private and public zoos across Arizona,…
-
Novavax filed for Emergency Use Authorization of COVID-19 vaccine in Taiwan
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food…
-
WHO and Medicines Patent Pool announced agreement with NIH for COVID-19 health technologies
On May 12, 2022, the World Health Organization (WHO) COVID-19 Technology Access Pool and the Medicines Patent Pool…
-
Cepheid received Emergency Use Authorization for Xpert Xpress CoV-2 plus
On May 12, 2022, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
-
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
-
Novavax submitted variations to expand Australian and New Zealand provisional approval of Nuvaxovid COVID-19 vaccine in Great Britain
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
-
Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
-
WHO reported 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021
On May 5, 2022, the World Health Organization (WHO) reported estimates that show the full death toll associated…
-
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
-
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
-
Veklury (Remdesivir) was first and only approved treatment for pediatric patients under 12 years of age with COVID-19
On Apr. 25, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental…
-
WHO recommended Paxlovid for high-risk COVID patients
On Apr. 22, 2022, the World Health Organization (WHO) made a strong recommendation for nirmatrelvir and ritonavir, sold…
-
Novavax announced initiation of COVID-19 vaccine booster study in adolescents in phase 3 PREVENT-19 trial
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
-
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
-
Initial results from Novavax’ COVID-19-Influenza vaccine trial were first to show feasibility of combination vaccine
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
-
Codiak announced new preclinical data supporting development of broadly protective pan beta-Coronavirus vaccine
On Apr. 20, 2022, Codiak BioSciences announced announc a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of…
-
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
-
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
-
COVID-19 booster effectiveness remained high during Omicron surge
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…
-
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines
On Apr. 18, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) of…
-
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
